An Open-label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin 30 mg/m2 Given Every 3 Weeks in Subjects With Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Anetumab ravtansine (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Bayer
- 19 Oct 2017 Planned number of patients changed from 40 to 61.
- 19 Oct 2017 Planned End Date changed from 7 May 2019 to 14 Sep 2019.
- 19 Oct 2017 Planned primary completion date changed from 25 Feb 2019 to 17 Aug 2019.